286 related articles for article (PubMed ID: 37587644)
1. Challenges and opportunities in the development of combination immunotherapy with OX40 agonists.
Redmond WL
Expert Opin Biol Ther; 2023; 23(9):901-912. PubMed ID: 37587644
[TBL] [Abstract][Full Text] [Related]
2. Current Clinical Trial Landscape of OX40 Agonists.
Yadav R; Redmond WL
Curr Oncol Rep; 2022 Jul; 24(7):951-960. PubMed ID: 35352295
[TBL] [Abstract][Full Text] [Related]
3. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
Redmond WL; Linch SN; Kasiewicz MJ
Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
[TBL] [Abstract][Full Text] [Related]
4. OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.
Linch SN; McNamara MJ; Redmond WL
Front Oncol; 2015; 5():34. PubMed ID: 25763356
[TBL] [Abstract][Full Text] [Related]
5. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
6. Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L; Rosas-Murrieta NH
Expert Opin Ther Pat; 2019 Dec; 29(12):921-924. PubMed ID: 31627712
[No Abstract] [Full Text] [Related]
7. Rationale for anti-OX40 cancer immunotherapy.
Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
[TBL] [Abstract][Full Text] [Related]
8. An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
Wang R; Gao C; Raymond M; Dito G; Kabbabe D; Shao X; Hilt E; Sun Y; Pak I; Gutierrez M; Melero I; Spreafico A; Carvajal RD; Ong M; Olszanski AJ; Milburn C; Thudium K; Yang Z; Feng Y; Fracasso PM; Korman AJ; Aanur P; Huang SA; Quigley M
Clin Cancer Res; 2019 Nov; 25(22):6709-6720. PubMed ID: 31573956
[TBL] [Abstract][Full Text] [Related]
9. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
Redmond WL; Triplett T; Floyd K; Weinberg AD
PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
[TBL] [Abstract][Full Text] [Related]
10. New pathways in immune stimulation: targeting OX40.
Alves Costa Silva C; Facchinetti F; Routy B; Derosa L
ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32392177
[TBL] [Abstract][Full Text] [Related]
11. Enhancing the Generation of Eomes
Emerson DA; Rolig AS; Redmond WL
Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
[TBL] [Abstract][Full Text] [Related]
12. OX40/OX40 ligand and its role in precision immune oncology.
Thapa B; Kato S; Nishizaki D; Miyashita H; Lee S; Nesline MK; Previs RA; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Metastasis Rev; 2024 Mar; ():. PubMed ID: 38526805
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a novel anti-OX40 antibody for potent immune activation.
Kuang Z; Jing H; Wu Z; Wang J; Li Y; Ni H; Zhang P; Wu W; Wu M; Zhou S; Qiu X; Wu D; Prinz B; Baruah H; Chen B; Yu M; Liu J
Cancer Immunol Immunother; 2020 Jun; 69(6):939-950. PubMed ID: 32078015
[TBL] [Abstract][Full Text] [Related]
14. Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis.
Shrimali RK; Ahmad S; Verma V; Zeng P; Ananth S; Gaur P; Gittelman RM; Yusko E; Sanders C; Robins H; Hammond SA; Janik JE; Mkrtichyan M; Gupta S; Khleif SN
Cancer Immunol Res; 2017 Sep; 5(9):755-766. PubMed ID: 28848055
[TBL] [Abstract][Full Text] [Related]
15. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Jahan N; Talat H; Curry WT
Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
[TBL] [Abstract][Full Text] [Related]
16. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor.
Gough MJ; Ruby CE; Redmond WL; Dhungel B; Brown A; Weinberg AD
Cancer Res; 2008 Jul; 68(13):5206-15. PubMed ID: 18593921
[TBL] [Abstract][Full Text] [Related]
17. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy.
Buchan SL; Rogel A; Al-Shamkhani A
Blood; 2018 Jan; 131(1):39-48. PubMed ID: 29118006
[TBL] [Abstract][Full Text] [Related]
18. Reprogramming macrophage by targeting VEGF and CD40 potentiates OX40 immunotherapy.
Liu Y; Ma Q; Yang K; Zhang D; Li F; Chen J; Zhou F; Wang H; Li N; Wang Y; Cao Y; Zhang C; Li X; Zhang H; Wang W; Li Y
Biochem Biophys Res Commun; 2024 Feb; 698():149546. PubMed ID: 38266314
[TBL] [Abstract][Full Text] [Related]
19. OX40 enhances T cell immune response to PD-1 blockade therapy in non-small cell lung cancer.
Lao J; Cao C; Niu X; Deng S; Ming S; Liang S; Shang Y; Yuan Y; Shi X; Liang Z; Wu M; Wu Y
Int Immunopharmacol; 2022 Jul; 108():108813. PubMed ID: 35580452
[TBL] [Abstract][Full Text] [Related]
20. Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1.
Perez-Santos M; Anaya-Ruiz M; Herrera-Camacho I; Millán-Pérez Peña L
Expert Opin Ther Pat; 2019 Jul; 29(7):481-485. PubMed ID: 31216214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
